#ESCCongress – RCT: In patients with A. Fibrillation who underwent TAVR, Edoxaban was noninferior to Vit. K Antagonist regarding the composite primary outcome of adverse clinical events, but resulted in a higher incidence of major bleeding.

Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR – New England Journal of Medicine

Commentaries:

ENVISAGE-TAVI AF: Edoxaban Disappoints in TAVI Setting – TCTMD

ENVISAGE-TAVI AF: Edoxaban vs. Warfarin Following Heart Valve Replacement – American College of Cardiology

Edoxaban vs. Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortic Valve Implantation–Atrial Fibrillation – ENVISAGE-TAVI AF – American College of Cardiology